Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer

摘要: Background: Only 25% of patients with HER-2/neu-positive metastatic breast tumors respond favorably to trastuzamab (Herceptin) treatment. We hypothesized that a high failure rate on could result if some the metastases were HER-2 negative and these ultimately determine course disease. Methods: used tissue microarrays (TMAs) containing four samples each from 196 lymph node-negative primary tumors, node-positive three different node tumor estimate gene amplification by fluorescence in situ hybridization (FISH) Her-2 protein overexpression immunohistochemistry (IHC). Results: FISH IHC analyses gave same respect status for 93.7% tissues contained TMAs. Tissue were, therefore, considered be positive they either DNA or expression both result. The was maintained majority their metastases. For HER-2-positive 77% (95% confidence interval [CI] = 59% 90%) had entirely metastases, 6.5% CI 8% 21%) HER-2-negative 16.3% 5% 34%) mixture 95% 88% 98%) HER-2. Conclusions: Our data suggest differences between cannot explain fraction nonresponders therapy.